TYRA BIOSCIENCES, INC.
TYRA
20.12
+0.39
+1.98%
TYRA BIOSCIENCES, INC.
US · TYRA
#3032 by market cap
Listed 2021
20.12
+0.39
+1.98%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.7 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 114.70% -2.68pp
- Institutions
- 202 -5
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund46.46%
VC/PE Fund40.83%
Hedge Fund24.13%
Individual/Insider2.27%
Public Company1.89%
Private Company0.62%
Sovereign Wealth Fund0.25%
Government Pension Fund0.20%
Endowment Fund0.18%
Insurance Company0.11%
Top holders as of 2026-09-15
RA Capital Management, L.P.
17.66% · 12.20M sh
FMR
15.25% · 10.54M sh
Janus Henderson Group plc
6.30% · 4.35M sh
BVF Partners L.P.
6.10% · 4.22M sh
Alta Partners LP
5.53% · 3.82M sh
Nextech Invest Ltd.
5.14% · 3.55M sh
Paradigm Biocapital Advisors LP
5.03% · 3.47M sh
Artal Group S.A.
4.92% · 3.40M sh
BlackRock
4.78% · 3.30M sh
T. Rowe Price Group, Inc.
4.05% · 2.78M sh
TCG Crossover Management, LLC
4.70% · 3.25M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 17.66% |
| Todd Harris | Chief Executive Officer | 1.97% |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 0.21% |
| Gilla Kaplan | Former Independent Director | 0.04% |
| Alan Fuhrman | Chief Financial Officer | 0.02% |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 0.02% |
| Adele M. Gulfo | Independent Director | 0.01% |
| Rehan Verjee | Independent Director | 0.00% |
| Alta Partners LP | -- | -- |
| Canaan Management, Inc. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Alan Fuhrman | Chief Financial Officer | Other Acquisition | +951 | $9.13 |
| 2026-09-14 | RA Capital Management, L.P. | -- | Open Market Derivative Acquisiti | +9,078,529 | $0.00 |
| 2026-09-14 | Todd Harris | Chief Executive Officer | Other Acquisition | +864 | $9.13 |
| 2026-09-14 | Julia Rueb | VP of Finance & Principal Accounting Officer | Other Acquisition | +2,925 | $9.13 |
| 2026-09-08 | Rehan Verjee | Independent Director | Open Market Acquisition | +971 | $20.58 |
| 2026-05-27 | Robert J. More | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Adele M. Gulfo | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Rehan Verjee | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | S. Rothenberg | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Jake Simson | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Susan Moran | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-04 | Alan Fuhrman | Chief Financial Officer | Other Acquisition | +20,000 | -- |
| 2026-05-04 | Alan Fuhrman | Chief Financial Officer | Other Derivative Acquisition | +67,000 | $33.93 |
| 2026-05-04 | Todd Harris | Chief Executive Officer | Other Acquisition | +79,000 | -- |
| 2026-05-04 | Todd Harris | Chief Executive Officer | Other Derivative Acquisition | +265,000 | $33.93 |
| 2026-05-04 | Bhavesh Ashar | Chief Operating Officer | Other Acquisition | +15,013 | -- |
| 2026-05-04 | Bhavesh Ashar | Chief Operating Officer | Other Derivative Acquisition | +50,295 | $33.93 |
| 2026-05-04 | Douglas Warner | Chief Medical Officer | Other Acquisition | +25,000 | -- |
| 2026-05-04 | Douglas Warner | Chief Medical Officer | Other Derivative Acquisition | +85,000 | $33.93 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.
TYRA BIOSCIENCES, INC. discussion 0 comments